Research
Exenatide — living evidence map
The Atlas page holds the claims; this is how its evidence evolved.
Summary
Exenatide (exendin-4) is an incretin mimetic studied for glycemic control in type 2 diabetes. · pmid:15855572
Mechanism
In rats with partial pancreatectomy, exendin-4, a long-acting GLP-1 agonist, stimulated beta-cell neogenesis and proliferation and attenuated the development of diabetes. · pmid:10580413
History
Over 30 weeks in metformin-treated patients with type 2 diabetes, it lowered HbA1c and produced dose-dependent weight loss compared with placebo, with mostly mild gastrointestinal adverse events. · pmid:15855572
In EXSCEL (14,752 patients, median 3.2 years), once-weekly exenatide was non-inferior to placebo for cardiovascular safety but not superior for efficacy (hazard ratio 0.91). · pmid:28910237
Identity
PubChem CID 45588096: Exenatide, C184H282N50O60S, 4187 g/mol. · pubchem:45588096
CAS registry number 141758-74-9. · pubchem:45588096
Where the evidence actually sits
Proportion of the 3 claims about Exenatide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
3 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Exenatide yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
- Approved-label dose · a resolved regulatory document names a labelled dose
nothing resolved on this rung
- Studied human doses · resolved human studies at the established tier
- Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. · pmid 15855572 · 2005
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. · pmid 28910237 · 2017
- Observational evidence · resolved human data at the emerging tier: thin, or contested
nothing resolved on this rung
- Community-reported protocols · protocol propositions from distinct members, counted once per human
nothing resolved on this rung
- Preclinical evidence · resolved animal, cell or mechanistic work
- Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. · pmid 10580413 · 1999
3 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.